Seroba Life Sciences

Seroba Life Sciences investment thesis

The Millipede88® is the first 088 aspiration catheter with patented corrugated technology cleared for standalone direct aspiration – no large-bore intermediary required- backed by independently adjudicated MARRS study data showing a 77% first-pass effect1 in M1 occlusions and 96% delivery success. Perfuze, a medical device company dedicated to advancing stroke treatment through next-generation catheter technology, today announced it has received … Medtech Explore Europe is a science powerhouse, but can it also lead in biotech and healthcare innovation? That’s the pressing question at the heart of Invest Europe’s  latest position paper:  “Biotech and Healthcare: The Venture Capital and Private Equity Perspective.” Seroba and BGV are proud to have led, along with Hadean, the development of I

Seroba Life Sciences team (8)

Partners and principals at Seroba Life Sciences:

• Jeanne Bolger — sweet spot $6M
• Andrew Duignan — sweet spot $6M
• Jennifer McMahon — sweet spot $6M
• Bruno Montanari — sweet spot $6M
• Alan O'Connell — sweet spot $6M
• Seamus O´Hara — sweet spot $6M
• Daniel O'Mahony — sweet spot $6M
• Peter Sandys — sweet spot $6M

Seroba Life Sciences portfolio companies

Companies listed on Seroba Life Sciences's public materials include: Team, Portfolio, Sustainability, News, Login LP, All, Medtech, Therapeutics, Latest News, Alveus Therapeutics, Azafaros, Shiratronics, Ryme Medical, Loci, Vico Therapeutics, Artica Therapeutics, Complement Therapeutics, Deciphex, Sibylla, Perfuze, Coave Therapeutics, Shorla Oncology, Storm Therapeutics, Palliare, Fusion Pharmaceuticals, Endotronix, Quanta, Medlumics, Veryan, Precision Biotics, Labcyte, 353 (0)1 633 4028, Linkedin, Legals, Credits.

Is Seroba Life Sciences a fit for your round?

Upload your pitch deck and see whether anyone at Seroba Life Sciences appears in your top matches.